Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Merlo

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Journal of Neurology, Neurosurgery, and Psychiatry|March 7, 2024
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60Yi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 19, 2022
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosisChao Zhu, Zhen Zhou, Izanne Roos, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 29, 2025
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosisYi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Therapeutic Advances in Neurological Disorders|November 11, 2024
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort studyDavid Levitz, Yi Chao Foong, Paul Sanfilippo, et al.
JAMA Neurology|June 5, 2023
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab CessationChao Zhu, Tomas Kalincik, Dana Horakova, et al.
Brain Communications|September 5, 2025
Persistent progression independent of relapse activity in multiple sclerosisChao Zhu, Zhen Zhou, Tomas Kalincik, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Journal of Neurology, Neurosurgery, and Psychiatry|March 7, 2024
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60Yi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 19, 2022
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosisChao Zhu, Zhen Zhou, Izanne Roos, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 29, 2025
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosisYi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Therapeutic Advances in Neurological Disorders|November 11, 2024
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort studyDavid Levitz, Yi Chao Foong, Paul Sanfilippo, et al.
JAMA Neurology|June 5, 2023
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab CessationChao Zhu, Tomas Kalincik, Dana Horakova, et al.
Brain Communications|September 5, 2025
Persistent progression independent of relapse activity in multiple sclerosisChao Zhu, Zhen Zhou, Tomas Kalincik, et al.
Pageof 3